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As people age, large elastic arteries become stiffer and cerebral arteries become 
dysfunctional. This research sought to determine whether treatment with pyridoxamine, 
a form of vitamin B6, prevents age-related arterial stiffening by limiting the increases in 
advanced glycation end products (AGEs), and thereby ameliorates the downstream 
consequences in cerebral arteries and cerebral cortex by limiting increases in oxidative 
stress and inflammation. 20 old mice were treated with pyridoxamine for 4 months and 
pulse wave velocity (PWV), a measure of aortic stiffness, was performed at baseline 
and every other month. Tissue samples from old control, young control, and old 
pyridoxamine treated mice were analyzed for gene expression of pro- and antioxidant 
enzymes and inflammatory cytokines. Aorta samples from each group were analyzed 
for AGEs by immunofluorescence and for thickness of the arterial wall by Verhoeff 
Van Gieson staining. Aortic PWV was greater in old control versus young control 
arteries (306 ± 12 cm/s vs. 273 ± 16 cm/s, p=0.005) however, aortic PWV in 
pyridoxamine-treated mice did not increase over time (p>0.05). Pyridoxamine did not 
change AGEs (0.05 ± 0.02 AU) versus old and young control arteries (0.01 ± 0.003 AU 
  
iii  
vs 0.1 ± 0.05 AU, p=0.10). There was no change to arterial wall structure between 
groups. In the cerebral cortex, SOD1 trended toward elevation in old pyridoxamine 
arteries as compared to old controls. IL-1β was significantly increased in old 
pyridoxamine versus young control (1.0 ± 0.29 AU vs. 3.2 ± 0.60 AU, p=0.03), the 
same was true in the MCA (1.0 ± 0.29 AU vs. 3.2 ± 0.60 AU, p=0.03). These results 
suggest that pyridoxamine may reduce arterial stiffening. While previous studies have 
indicated a reduction in AGEs with pyridoxamine treatment, this was not evident in the 
present study. Pyridoxamine may increase SOD1 expression, while increases in IL-1β is 
likely a result of the aging process and not modified by pyridoxamine treatment. Further 
studies are needed to identify the mechanism by which pyridoxamine prevents age-
related arterial stiffening. 
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Introduction 
Aging is inevitable. Both nationally and globally, populations are aging rapidly. 
A recent report by the U.S. Census Bureau states that by 2035, there will be more adults 
over the age of 65 than children under age 18 for the first time in American history 
(Bureau, 2018). However, as a result of the aging population there is an increase in 
diseases associated with age. Concurrent projections suggest that 132 million people 
will have at least one type of cardiovascular disease (CVD) by 2035, an increase from 
102.7 million people in 2015 (Khavjou, Olga, Phelps, Diane, & Leib, 2016). Trends 
also indicate that the incidence of chronic kidney disease, another disease associated 
with advancing age, will increase over the same time frame (Stevens, Viswanathan, & 
Weiner, 2010). Although some evidence suggests that the prevalence of dementia and 
related cognitive disorders within age groups is decreasing, the rapid expansion of the 
elderly population will spark an associated rise in neurocognitive disorders (Y.T. Wu et 
al., 2017). Thus, it is expected that, barring any major medical breakthrough, the 
dramatic rise in older individuals with these conditions will outpace the expansion in 
the support network of caregivers and healthcare providers and cause a crisis in elder 
care (Seals, Justice, & Larocca, 2016; Warshaw & Bragg, 2014).  
Globally, improvements in healthcare, sanitation, and medical knowledge have 
rapidly improved median human lifespan, but this has triggered an increase in the 
development of aging diseases (Thorin-Trescases et al., 2018). Increasingly, the 
scientific community has begun to place greater emphasis on understanding and 
preventing the underlying mechanisms of aging; it is therefore imperative to understand 
the fundamental mechanisms of aging. This project examined a pharmaceutical agent, 
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pyridoxamine, and sought to elucidate the mechanism by which it alters large artery 
stiffening and thus potentially alleviates the downstream consequences such as 
diminished cerebral artery function, increases in vascular inflammation and oxidative 
stress, and neuroinflammation.  
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What is Aging?  
At the cellular level, aging results from the accumulation of damaged 
macromolecules within a cell (McDonald, 2014). Once organisms reach adulthood, the 
rate of damaged macromolecule buildup begins to surpass the rate of breakdown, 
altering normal cellular function (McDonald, 2014). While aging itself is not considered 
a disease, it is a major risk factor for a variety of diseases ranging from cognitive 
disorders and cancer to CVD (Seals et al., 2016).  
Innovative technologies and medical advances have successfully increased 
median lifespan in humans; however, most are reactive rather than preventative and do 
not address the underlying biochemical pathways that cause aging. Proposed 
mechanisms of vascular aging include mitochondrial dysfunction, inflammation, 
epigenetics, damage to telomeres, oxidative stress, and cellular senescence (Seals et al., 
2016). These mechanisms likely feedback cyclically on one another – for example, 
increases in oxidative stress lead to increases in inflammation, which in turn causes 
oxidative stress to increase (Seals et al., 2016).  
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Cardiovascular Aging  
Changes to the cardiovascular system have long been identified as potential 
causative agents in poor aging. In fact, stiffening in the large elastic arteries is a 
powerful indicator of future CVD (Scuteri et al., 2007). Arterial stiffness also serves as 
a predictor of future diagnosis of dementia in patients with existing mild cognitive 
impairment (MCI) (Rouch et al., 2018). A study of 375 patients with MCI over six 
years found that increased pulse wave velocity (PWV), a measure of arterial stiffness, 
was the only factor associated with a greater risk of dementia after controlling for age 
and other confounding variables (Rouch et al., 2018). This outcome suggests that 
arterial stiffening with age plays a role in the development and worsening of dementia 
and neurocognitive disorders. 
As arteries throughout the body stiffen, there is a chronic increase in the 
resistance the heart must work against to pump blood into the aorta and throughout the 
body (Seals, Jablonski, & Donato, 2011). Increased total peripheral resistance (TPR) 
causes extra stress on the heart and cardiovascular system combined with dietary and 
lifestyle factors can eventually lead to heart attack, stroke, and other cardiovascular 
dysfunction (Seals et al., 2011). Cardiovascular damage is also linked to the 
development of cognitive disorders associated with aging such as Alzheimer’s disease 
and dementia (Seals et al., 2011).   
Pulse pressure (the difference between systolic and diastolic blood pressure) 
widens with age, increasing the differential pressure blood vessels are subject to 
(Thorin-Trescases et al., 2018). Research suggests that stiffened arteries transmit the 
pulse wave at greater pressure further into the vasculature, causing the walls of smaller 
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and smaller vessels to oscillate more and thus causing more mechanical damage 
(Thorin-Trescases et al., 2018). Blood vessels in the brain are smaller and more fragile 
than large elastic arteries such as the aorta and thus are more susceptible to damage 
from increased pulsatility and blood pressure (Thorin-Trescases et al., 2018). The pulse 
is transmitted with greater force into the vasculature which may be a cause of 
endothelial dysfunction (Thorin-Trescases et al., 2018).  
Molecular Mechanisms of Cardiovascular Aging  
With age, a variety of biochemical changes lead to reduced arterial compliance, 
the ability of a vessel to expand in response to increased pressure. Smooth muscle cells 
migrate into the tunica intima, the innermost layer of an artery, affecting the ability of 
substances to diffuse into the arterial wall and reducing the vessel’s ability to dilate and 
constrict (Bilder, 2016). Decreased bioavailability of nitric oxide (NO), increased 
superoxide concentration, and formation of advanced glycation end products (AGEs) 
that cross-link collagen fibers in tunica adventitia all act to inhibit a vessel’s dilatory 
capacity (Seals et al., 2011). Over time, evidence suggests there is also increased 
presence of collagen proteins and decreased elastin and thus more collagen and fewer 
elastic fibers in the arteries, further contributing to increased arterial stiffness (Henson, 
Walker, Reihl, Donato, & Lesniewski, 2014).   
Oxidative stress is the result of oxidation-reduction reactions that form 
byproducts such reactive oxygen species (ROS) (McDonald, 2014). One common ROS 
is superoxide, which is primarily produced by NADPH oxidase (NOX) and by leaks in 
the electron transport chain within the mitochondria during cellular respiration 
(Harrison, 2012). ROS and other reactive species serve important functions in normal 
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cellular activity; for example, immune cells use superoxide radicals to kill bacteria or 
foreign substances while other cell types use them for signaling purposes (Harrison, 
2012). However, with age research suggests that arterial NOX activity increases 
(Ungvari, Kaley, de Cabo, Sonntag, & Csiszar, 2010). A localized buildup of these 
byproducts causes intercellular damage by reacting with proteins and other molecules in 
the cell, altering their structure and thus, impairing their function (McDonald, 2014). 
While there are antioxidant enzymes specifically designed to breakdown ROS such as 
superoxide dismutase (SOD), catalase, and glutathione peroxidase, the rate of 
superoxide production eventually surpasses the rate at which SODs are able to break 
them down (Bilder, 2016).  
AGEs are another significant contributor to arterial stiffness. AGEs are formed 
via the oxidation of proteins that then covalently bond to a sugar and lysine or arginine 
group, thus altering the structure of the protein (Bilder, 2016). In collagen fibers, AGEs 
go on to form cross-links with each other making an already stiff protein (collagen) all 
the more inflexible and decreasing arterial malleability (Bilder, 2016). Collagen is an 
important structural component of arteries as it provides shape and support, however, 
increased cross-linkage can be damaging (McDonald, 2014). When the artery stiffens, it 
decreases vascular compliance and causes degeneration of the collagen scaffold, 
indirectly impacting the cell’s ability to communicate with its external environment 
(Bilder, 2016). Because AGEs are resistant to breakdown, they impact collagen fiber 
function in tissues throughout the body such as the kidney and cornea in addition to 
arteries (Bilder, 2016).  
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NO is a local vasodilator and an antioxidant (Bilder, 2016). NO in the 
vasculature is produced by endothelial nitric oxide synthase (eNOS). With increased 
age, there is decreased bioavailability of NO (Bilder, 2016). This is the result of 
reactions with ROS that inhibit the activity of NO, thus reducing the amount available 
for the cell to use (Harrison, 2012). Furthermore, with age there is a decrease in eNOS 
expression which means less NO is produced overall (Ungvari et al., 2010). With age, 
eNOS can become uncoupled due to a reduction in the available cofactor and can 
therefore produce superoxide rather than NO (Yang, Huang, Kaley, & Sun, 2009). NO 
acts as an inhibitor of adhesion molecules which signal inflammatory processes to 
occur, thereby halting inflammatory signaling (Harrison, 2012). Reduction of 
bioavailability of NO therefore indirectly increases inflammation (Harrison, 2012). All 
of these mechanisms and factors compound to cause cellular damage and decrease the 
function of the cells, and thus tissues and organs leading to external makers of the aging 
process.  
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Preventative and Pharmaceutical Measures 
Currently, the most effective preventative measures against aging are diet and 
exercise (Seals et al., 2016). In physically active individuals, body systems that 
typically decline with age such as respiratory fitness or cardiovascular health are 
significantly improved as compared to those individuals leading sedentary lifestyles 
(Seals et al., 2016). Surprisingly, those who become physically active later in life after 
periods of inactivity as young adults have similar aging profiles to those who have 
remained active throughout life, suggesting that beginning exercise later could still be a 
valuable preventative measure (Seals et al., 2016).   
Chronic aerobic exercise is also shown to reduce inflammation and oxidative 
stress and therefore leads to maintained or improved bioavailability of NO (Seals et al., 
2016). Superoxides and other (ROS) are byproducts of metabolism that react with and 
inhibit cellular components. It therefore follows that with chronic exercise, less 
superoxide is available to interact with NO, and thus more is available to regulate local 
vasodilatory responses (Seals et al., 2016).   
Diet also plays a prominent role in preventing or delaying negative aging 
processes. Restricted calorie diets are shown to increase lifespan and decrease age-
related damage to several body systems including the cardiovascular system (Seals et 
al., 2016). Specifically, caloric restriction has been shown to reduce endothelial 
dysfunction and arterial stenosis (Seals et al., 2016). However, caloric reduction and 
exercise are not necessarily viable options for all individuals. For example, among older 
adults, calorie-restricted diets could lead to malnutrition and existing disabilities or 
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motor impairments may inhibit the ability to exercise (Seals et al., 2016). Thus, it is 
important to identify other potential preventative measures.  
Pyridoxamine and Vascular Aging 
The goal of this research was to identify possible pharmaceutical interventions 
to prevent the damaging effects of arterial stiffening in large elastic arteries. 
Pyridoxamine is a naturally-occurring form of the vitamin B6. It is hypothesized to 
prevent the formation of AGEs which are implicated in arterial stiffening (Chang, 
Liang, Tsai, Wu, & Hsu, 2009).  
Chang et al. induced diabetes in a set of rat models and then treated half for 
eight weeks with pyridoxamine (Chang et al., 2009). The pyridoxamine-treated rodents 
displayed decreased wave reflection in the aorta, a marker of arterial stiffness, 
suggesting that their arteries were less stiff than those of the control rats (Chang et al., 
2009). Additionally, pyridoxamine treatment inhibited the hypertrophy of the left 
ventricle typically seen in diabetes (Chang et al., 2009). More significantly, collagen 
cross-linking as a result of AGEs was significantly decreased in the treated group 
(Chang et al., 2009). Chang et al. (2009) hypothesized that pyridoxamine inhibits AGEs 
in three ways: stopping the formation of AGEs by getting rid of toxic oxidative 
byproducts, removal of metal ions, and inhibition of the Amadori intermediate 
breakdown. 
 In a similar study, aged rats treated with pyridoxamine were compared to young 
counterparts (E. T. Wu, Liang, Wu, & Chang, 2011). Treated rats showed significantly 
fewer AGEs after 5 months (E. T. Wu et al., 2011). Furthermore, the body weight of 
aged rats decreased 7.2% over the course of treatment (E. T. Wu et al., 2011). The 
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increase in TPR typically seen in aged arteries was reduced significantly in 
pyridoxamine-treated rats (E. T. Wu et al., 2011). Wu et al. (2011)posited that by 
reducing the development of AGEs, more NO was available and thus the dilation of the 
arteries was preserved. 
Preliminary data from our lab suggests that pyridoxamine partially prevents age-
related reductions in endothelial function in the middle cerebral artery (MCA) (Figure 
1). However, the mechanism by which pyridoxamine preserves dilatory capacity is 
unknown.  
 
Figure 1. Pyridoxamine partially preserves endothelial function in MCAs of old treated 
animals 
A. Dilation of MCAs in response to increased doses of acetylcholine, an endothelium 
dependent dilator via eNOS. Pyridoxamine improves vasodilation as compared to old 
control animals; B. Dilation in response to increased doses of sodium nitroprusside, an 
endothelium-independent dilator. This demonstrates that the decrease in dilation with 
age is due to endothelial dysfunction. 
Therefore we examined the pyridoxamine’s effect on aortic stiffness and 
morphology, MCA and brain tissue inflammation to establish this relationship. We 
posited that pyridoxamine inhibits large artery stiffening and prevents downstream 
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consequences such as endothelial dysfunction which preserves cognitive function 
(Figure 2).  
 
Figure 2. Proposed mechanism by which pyridoxamine mitigates cerebral arterial 
aging. 
Pyridoxamine has been shown to inhibit large artery stiffness and therefore we 
hypothesize that it reduces endothelial function and the downstream development of 
cognitive impairment and cerebral inflammation with age.  
We hypothesized that treatment with pyridoxamine will prevent age-related 
arterial stiffening and thereby preserve cerebral artery function by limiting the increase 
in oxidative stress and associated dysfunction, which will in turn prevent increases in 
neuroinflammation. 
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Methods 
Model Organism: C57BL6 Mice 
Young and old male C57BL6 mice were used as a model of naturally occurring 
arterial aging. Characteristics of young, old control, and old treated animals used in 
gene expression and immunofluorescence experiments appear in Table 1. Figure 3 
provides the breakdown of each group of mice and how they were used in the present 
study.  
 
Figure 3. Schematic of animal treatment groups and their uses 
Group 1 consisted of 8 treated and untreated middle-aged mice whose tissues were 
collected after 6 months of pyridoxamine treatment or vehicle control. Group 2 
consisted of 20 pyridoxamine treated mice for whom PWV was measured prior to 
treatment and then every other month for 4 months.  
20 mice were given pyridoxamine in water (1 mL pyridoxamine/384 mL water) 
ad libitum for 4 months. Mice treated with pyridoxamine for PWV were 21 months old 
at the start of treatment. Old control mice were 25 and 27 months old and young control 
mice were 4 months old when PWV was measured. Mice from whom tissues were 
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collected were 7.4 and 24.8 months old for young and old control, respectively (Table 
1). Old pyridoxamine mice were 24.8 months old at tissue collection (Table 1). 
 
Young 
Control 
Old 
Control   Old Pyridoxamine 
  Pre Post Pre Post 
n 10   11   13 
Age, 
months 7.4 ± 0.1  24.8 ±0.2*  24.8 ±0.2* 
Body mass, 
g 28.7 ± 0.9 33.0 ±0.4* 32.0 ±0.4* 33.7 ±0.5* 31.5 ±0.6* 
Table 1. Characteristics of Young and Old Animals from which Tissues were Collected, 
adapted from Walker 
Masses and ages of young animals at time of testing and old animals pre and post 
treatment. * indicates significance as compared to young control (p<0.05).  
Mice are a valuable model organism because the structure of their cerebral 
arteries mirrors that of humans – both humans and mice have a Circle of Willis which 
supplies blood to the brain (Figure 4). Female mice were not used because they do not 
undergo a menopause similar to that of human women and thus have higher levels of 
estrogen throughout their lifespans. Estrogen has a significant protective effect against 
aging. Mouse weight was assessed weekly during the treatment period. 
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Figure 4. Mouse and Human Brains with MCA highlighted 
The image on the left shows a mouse brain with the MCA indicated by a red arrow 
(Walker, unpublished). The image on the right illustrates a human brain with the MCA 
indicated by a pink highlight (“Anatomy & Physiology Revealed v3,” 2017). The Circle 
of Willis (pathway of arterial circulation) is evident in both images.  
PWV as a Measure of Aortic Stiffness 
PWV of the aorta was measured using previously described methods (Walker et 
al., 2015). Mice were exposed to 2% inhaled isoflurane and oxygen until anesthetized 
and carefully secured to a surgical heating platform at 39˚C in a supine position (Walker 
et al., 2015). Anesthesia was maintained with a nose cone supplying a constant stream 
of 2% isoflurane and oxygen (Walker et al., 2015). Velocities of the transverse aortic 
arch and abdominal aorta were measured using 20 MHz Doppler probes (Indus 
Industries, Webster, TX, USA) and recorded simultaneously using Indus software 
(Indus Industries) (Walker et al., 2015) (Figure 5). 
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Figure 5. Experimental Pulse Wave Velocity Setup, adapted from Henson 
Mouse is anesthetized and secured to a surgical platform with a nose cone (not 
pictured) providing a constant supply of oxygen and isoflurane, Doppler probes are 
placed on the arch of the aorta and abdominal aorta, respectively. Recordings of blood 
velocity and EKG over time are obtained. To analyze, markers are placed in the 
indicated locations and the distance between the probes is measured.  
 Once the data were collected, the distance between the probes was measured 
using calipers (Walker et al., 2015).  
Immunofluorescence 
Sections of thoracic aorta were frozen in optimal cutting temperature (OCT) and 
then sliced into 8 𝜇𝜇𝑚𝑚 sections using a cryostat (Nikon, Minato, Tokyo, Japan) and 
adhered to a charged slide (Walker et al., 2015). For each animal, 10 slides were 
prepared with 4 sections of artery per slide. To begin staining, OCT was removed with 
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forceps and slides were rehydrated in acetone for 10 minutes. A PAP pen was used to 
draw a circular hydrophobic barrier around each artery and slides were incubated in a 
blocking buffer (0.1% Triton-X, 1% BSA, PBS) for 15 minutes. To quantify AGEs, 
three arterial samples on each slide were stained with a primary antibody anti-
carboxymethyl lysine (AbCam 27684, AbCam, Cambridge, England, UK) at a 
concentration of 1:100 while the fourth served as a control and was incubated in only 
blocking buffer for 2 hours. All samples were subsequently incubated with Alexa Fluor 
647 (AF-647) (Life Technologies, Grand Island, NY, USA) secondary antibody for 1 
hour. Slides were then mounted with Prolong Gold with DAPI (Life Technologies) to 
stain cell nuclei and coverslips were applied and allowed to dry. Images of the artery 
were taken using a Zeiss LSM 880 Confocal Microscope SR-SIM (Zeiss, Oberkochen, 
Germany) with three filters applied to show autofluoresence of elastic lamina in the 
FIT-C channel, cell nuclei in the DAPI channel, and AGEs in the AF-647 channel 
(Walker et al., 2015). AGEs images were then obtained for each aortic section using 
only the AF-647 channel.  
Verhoeff-Van Gieson Staining 
Arterial samples were stained via Verhoeff-Van Gieson (VVG) stain to 
determine the structure of the arterial wall (Walker et al., 2015). Slides of aortas were 
obtained via the same cryostat procedure described above and submerged in 10% 
neutral buffered formalin for 10 minutes. Slides were then rinsed in tap water and RO 
water. Slides were placed in working elastic stain solution (Ferric chloride solution, 
Weigert’s Iodine solution, Hematoxylin solution, dH2O; Sigma-Aldrich, St. Louis, MO) 
and rinsed again in tap water and subsequently in RO water. Slides were then placed in 
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working ferric chloride solution to lighten the stain for 1.5 minutes, stained with Van 
Gieson solution, and dehydrated using a series of increasing ethanol concentrations to 
xylenes over the course of 18 minutes. Histological samples were mounted with 
Permount mounting medium (Electron Microscopy Sciences, Hatfield, PA) and 
coverslips were applied. Slides were allowed to dry and imaged using a Leica 
Microscope (Leica, Wetzlar, Germany) and Leica LAS software (Leica).  
Real-time Gene Expression 
 Gene expression was examined by real-time PCR, a technique that amplifies 
DNA samples to a measurable amount, to quantify the amount of each gene of interest 
present in the tissue of interest. RNA was isolated from cerebral cortex samples of 
young, old control, and old pyridoxamine treated mice using the RNAeasy Mini kit 
(Qiagen, Hilden, Germany) (Walker et al., 2015). 500 µL of Qiazol was added to frozen 
cortex samples and allowed to thaw. Samples were then mixed using a homogenizer and 
loaded into the QiaShredder column. Samples were centrifuged and chloroform was 
added. Samples were then centrifuged for 15 minutes at 4˚C and the aqueous layer was 
transferred to a new tube. 1.5 volumes of 100% ethanol were added, then samples were 
added to the RNeasy mini column and centrifuged with a series of RW1 and RPE 
buffers. Water was added to the column and the RNA was collected in a new tube. 
MCAs were isolated using a slightly modified protocol to increase RNA yield. Arteries 
were flash-frozen in liquid nitrogen and crushed with a homogenizer tip before Qiazol 
was added and after thawing, samples were Sonicated for 2 minutes at 50% power. 
Columns from the Qiagen RNAeasy Micro Kit (Qiagen) were used in place of the 
RNAeasy Mini Kit (Qiagen) due to the small size of the arteries. All RNA samples were 
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Nanodropped to determine the amount (ng/µL) of nucleic acid. RNA was then 
converted to cDNA using the Qiagen Reverse Transcriptase Kit (Qiagen). Based on 
Nanodrop values, gDNA wipeout, water, and the calculated volume of RNA were 
added to a tube and incubated for 2 minutes at 42˚C. reverse transcriptase (RT) buffer, 
RT, and RT primer mix were added, and the samples were incubated at 42˚C for 15 
minutes. The temperature was increased to 95˚C for 3 minutes then removed from heat. 
Samples of cDNA were diluted appropriately (80 µL dH2O in cerebral cortex samples, 
25 µL dH2O in MCAs). The cDNA was then amplified with primers to bind to genes of 
interest and was analyzed for the expression of those genes in each experimental group. 
Cortex samples were examined for expression of reporter gene 18S and subsequently 
for expression of IL-1β, TNFα, NOX1, NOX2, SOD1, SOD2, and SOD3. MCA 
samples were studied for expression of reporter gene 18S and subsequent expression of 
NOX2, SOD1, and IL-1β. 
Data Analysis 
To analyze PWV data, Indus software (Indus Industries) was used to determine 
absolute pulse arrival times based on the foot of each waveform (Walker et al., 2015). 
Calculation of the aortic PVW was determined by the fraction of distance between the 
probes divided by the difference in absolute arrival times (Walker et al., 2015). 
Immunofluorescence and VVG data were analyzed using ImageJ software (NIH, 
Bethesda, MD). Immunofluorescence analysis for AGEs images in ImageJ (NIH) 
consisted of tracing the arterial structure in the composite image using the elastic lamina 
as a guide, applying this trace to the individual AGEs images, setting a threshold of 75 
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to eliminate background brightness, and measuring the mean gray value (Walker et al., 
2015).VVG analysis consisted of examining the differences in thickness of the aorta 
between young, old control, and old treated mice using ImageJ software (NIH) by 
tracing the inner and outer walls of the artery and calculating the area for each section 
then averaging the results (Walker et al., 2015). This method was repeated twice for 
each artery image, once taking into account the elastic lamina only and once taking into 
account both the elastic lamina and tunic adventitia. Gene expression was determined 
by normalizing each gene to the expression of 18S and calculating the 2^ddCT. Data are 
reported as average ± SEM.  
Statistics 
Statistical analyses were conducted using SPSS and Prism. Group differences 
were compared by one-way ANOVA. A post-hoc Tukey’s multiple comparisons test 
was run if ANOVA results were significant to determine differences between groups. 
Significance was set at p<0.05.  
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Results 
PWV 
Heart rate during PWV measurement was not different between groups (Table 
2). PWV is significantly increased in old control mice as compared to middle-aged mice 
prior to pyridoxamine treatment and young control mice (p=0.005) (Figure 6). 
Pyridoxamine resulted in lowered PWV two months into treatment as compared to old 
control mice tested at four months but was not different after four months of treatment 
(p > 0.05) (Figure 6). PWV did not differ significantly over the course of pyridoxamine 
treatment in old mice (p=0.11). 
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Group Heart Rate (bpm) 
Pretreatment 442 ± 12 
2 Months Treatment 416 ± 9 
4 Months Treatment 440 ± 14 
Old Control 455 ± 13 
Young Control 405 ± 14 
Table 2. Average Heart Rates of Mice During PWV 
Heart rate was not different between groups during PWV testing. Data are reported as 
Average ± SEM.  
 
Figure 6. PWV of pyridoxamine treated animals versus treatment time and PWV 
comparison between young control, old control, and pyridoxamine treated groups 
A. PWV (cm/s) over a treatment period of 4 months. There was no significant change 
in PWV over the course of 4 months of treatment. B. PWV at 4 months of 
pyridoxamine treatment course compared to young control and old control mice at the 
4-month time point. Old control mice had significantly increased PWV as compared to 
young control and pretreatment middle-aged mice, † indicates significance versus 
young control (p<0.05).  
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AGEs Immunofluorescence  
Young mice trended toward having fewer AGEs than old control mice in the 
aorta (p=0.08) (Figure 7). AGEs in the pyridoxamine treated animals were not different 
than old or young control mice (p=0.10) (Figure 7). 
 
Figure 7. Pyridoxamine does not alter AGEs in pyridoxamine-treated aortas 
A. AGEs in the aorta of young control, old control, and old pyridoxamine treated mice. 
AGEs quantified with ImageJ, no significant difference between groups; B. Aortas 
stained via immunofluorescence for AGEs. Green indicates elastin, blue indicates cell 
nuclei, and red indicates AGEs. Left to right: young untreated aorta, old untreated aorta, 
old pyridoxamine treated aorta.  
VVG Staining 
The overall thickness of the aortic wall was unchanged between young, old 
treated, and old control subjects (p=0.3) (Figure 8). Treatment also did not alter 
adventitial thickness between young, old control, and old treated groups (p=0.4) (Figure 
8). However, young animals trended toward having thinner aortas.  
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Figure 8. Pyridoxamine does not alter arterial wall structure in treated aortas 
A. Area of the aortic wall in µm2, no difference between young control, old control, and 
pyridoxamine treated arteries; B. Area of the aortic adventitia in µm2, no difference 
between groups; C. Aortas stained with Verhoeff Van-Gieson stain for elastin and 
collagen. Pink indicates collagen, purple indicates elastin. Left to right: young untreated 
animal, old untreated animal, old pyridoxamine treated animal.  
MCA Gene Expression 
In the MCAs, gene expression of SOD1 was not different between groups 
(p>0.05). However, IL-1β was significantly higher in pyridoxamine treated animals 
than young control animals (p=0.03) (Figure 9). NOX2 trended toward being elevated 
in old control MCAs as compared to young control and old pyridoxamine animals 
(p=0.092) (Figure 9).  
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Figure 9. MCA expression of IL-1β (AU) is increased in old pyridoxamine vs. young 
control; Expression of NOX2 trends higher in old control vs. young control and old 
pyridoxamine. Expression of SOD1 is not changed between groups.  
A. Gene expression of IL-1β is elevated in pyridoxamine as compared to young control 
animals. No difference between old control and pyridoxamine treated. No difference 
between young and old control animals. * indicates significance versus young control 
(p<0.05); B. Expression of NOX2 trends toward elevation in old control versus young 
control and old pyridoxamine MCAs. C. SOD1 is not different between the three 
groups.  
Cerebral Cortex Gene Expression 
In the cerebral cortex, SOD1 trended toward being reduced in pyridoxamine 
treated animals as compared to old control animals and thus similar to values seen in 
young controls (p=0.1) (Figure 10). NOX2 was significantly elevated in pyridoxamine 
treated mice as compared to old control animals (p=0.04) (Figure 10). IL-1β was 
significantly increased in old pyridoxamine as compared to old control mice (p= 0.05) 
(Figure 10). SOD2 and SOD3 were not different between groups (p>0.05). Expression 
of TNFα and NOX1 in the cerebral cortex was too low to quantify.  
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Figure 10. Cerebral cortex expression of NOX2 is higher in old pyridoxamine vs. old 
control; Expression of IL-1β is significantly elevated in old pyridoxamine vs. old 
control; Expression of SOD1 trends higher in young control and old pyridoxamine. 
A. Expression of IL-1β (AU) is significantly elevated in pyridoxamine treated as 
compared to old control mice; B. Expression of NOX2 (AU) is significantly elevated in 
pyridoxamine treated as compared to old control mice; C. Expression of SOD1 trends 
toward being higher in old pyridoxamine treated animals than old control animals; * 
indicates significance versus old control (p<0.05). 
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Discussion 
In the present study we treated mice with pyridoxamine for four months to 
determine the mechanism by which pyridoxamine attenuates cerebral artery endothelial 
dysfunction in old mice and somewhat preserves dilatory response to a NO-mediated 
dilator (Figure 1). We found that pyridoxamine prevents the expected increase in PWV. 
However, contrary to our hypothesis, treated mice had increased expression of IL-1β 
and NOX2, both pro-oxidants, in the cerebral cortex. The trend toward greater 
expression of SOD1 in the cortex supported the hypothesis that pyridoxamine increases 
antioxidants. In the MCA, IL-1β was also significantly elevated and NOX2 trended 
toward being decreased, however, SOD1 was not affected by pyridoxamine treatment. 
Therefore, pyridoxamine may prevent age-related increases in large artery stiffness, but 
also increase pro-inflammatory and pro-oxidant factors in the brain.   
Pyridoxamine attenuates PWV somewhat after 4 months of treatment   
These data agree with previous literature stating that PWV increases with age 
(Di Lascio, Stea, Kusmic, Sicari, & Faita, 2014) – old control mice had significantly 
greater PWV than both young control and middle-aged mice prior to pyridoxamine 
treatment. However, pyridoxamine treated mice did not have increased PWV after 4 
months of treatment, suggesting that pyridoxamine may attenuate arterial stiffening 
with age. We do not have the same time course of PWV measurements for the old 
control mice, thus it cannot be said with certainty that pyridoxamine prevents age-
related increases in PWV. Nevertheless, our result concurs with prior studies suggesting 
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that pyridoxamine prevents arterial stiffening (Chang et al., 2009; E. T. Wu et al., 
2011), but the mechanism remains unclear.  
Pyridoxamine does not alter AGEs or arterial wall structure 
These results suggest that pyridoxamine treatment does not prevent the 
formation of AGEs in large elastic arteries. While previous studies have indicated a 
reduction in AGEs with pyridoxamine treatment, this was not evident here. It is possible 
that our method for measuring AGEs (immunofluorescence) was not sensitive enough 
to detect differences with pyridoxamine treatment. Therefore future studies will 
measure AGEs via Western blot, similar to previous studies (E. T. Wu et al., 2011). As 
anticipated, treatment has no effect on the structure of the arterial wall in aged mice. 
These results suggest that the improvement in MCA vasodilation with pyridoxamine 
treatment and perhaps the age-related increase in PWV, were not due to a reduction of 
AGEs in the aorta. 
Pyridoxamine’s effect on oxidative stress and inflammation 
Oxidative stress refers to the increase in reactive byproducts that alter cellular 
function. Antioxidant enzymes such as SOD1 breaks down ROS and helps maintain the 
balance between overproduction of damaging ROS and a sufficient quantity to maintain 
cellular immune function (Harrison, 2012). SOD1 also likely plays a role in mitigating 
cellular senescence (Harrison, 2012). With increased age, there is a reduction in mRNA 
expression of SOD1 in rodent brain tissue (Semsei, Rao, & Richardson, 1991). 
Furthermore, mice that are missing both copies of the SOD1 gene have accelerated 
aging profiles and decreased lifespans (Y. Zhang et al., 2017). Our data suggest that 
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young mice trend toward having more SOD1 in the cerebral cortex and are therefore 
better able to break down ROS. While there is no significant difference in old control 
and old treated animals, SOD1 trends toward restoration to young values in 
pyridoxamine-treated brains suggesting a possible role for pyridoxamine improving 
expression of SOD1. SOD2 and SOD3 were not affected by pyridoxamine treatment, 
likely because SOD1 is the only cytoplasmic form of the enzyme and thus perhaps more 
relevant to arterial function.  
IL-1β is a pro-inflammatory cytokine released as a part of the body’s response to 
inflammation. With age, there is an increase in systemic inflammation and therefore IL-
1β is elevated (Csiszar, Ungvari, Koller, Edwards, & Kaley, 2003). The increase of IL-
1β in cortex samples appears to be a result of pyridoxamine treatment. However, the 
increase seen in the MCAs of pyridoxamine-treated animals is likely a result of the 
aging process as it is similarly (although not significantly) elevated in old untreated 
arteries. In serum samples, Zhang et al. (2016) similarly found that injection 
pyridoxamine had little effect on the production of IL-1β. Further, they found that 
pyridoxamine did not alter the expression of IL-1β mRNA (P. Zhang et al., 2016). 
Thus, pyridoxamine appears to have little effect on the reduction of IL-1β expression. 
NOX2 is an enzyme that produces superoxide, a ROS, that helps maintain 
immune function (Harrison, 2012). However, with age there is an increase in activity of 
NOX and a decrease in antioxidant enzymes to break ROS down (Ungvari et al., 2010). 
Cerebral cortex expression of NOX2 was increased in pyridoxamine treated as 
compared to old control animals, suggesting an increase in ROS. MCA expression of 
NOX2 trended toward being reduced to young control levels, which was in line with 
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expectations of reduced ROS. A study of the effect of pyridoxamine on high- and low-
fat diet versus control diets in mice found that pyridoxamine treatment reduced NOX 
expression (Hagiwara et al., 2009). They concluded that the decrease in NOX activity 
was an effect of lowered fat accumulation rather than a direct effect of pyridoxamine 
(Hagiwara et al., 2009). However, that study did not take into account the effects of 
aging, so the increase in NOX2 in the MCAs and cerebral cortex may be a result of 
aging. Furthermore, it is possible that alterations to gene expression in the cerebral 
cortex are the result of a different pathway than in the MCAs.  
In this study, we also measured the expression of TNFα, a pro-inflammatory 
cytokine, and NOX1 a pro-oxidant enzyme, in the cerebral cortex. However, the 
expression of TNFα and NOX1 were too low to be quantified. 
Limitations 
This study has a significant limitation in that it did not track PWV in old control 
mice with increasing age concurrently with treated mice. Thus, it is unclear whether 
pyridoxamine limits the increase in PWV as compared to old control animals over time. 
Another set of mice with both treatment and control groups should be studied 
longitudinally. We were unable to examine protein expression due to the small sizes of 
the arterial tissues. However, the amount of protein expressed is typically more 
physiologically important than gene expression. Group sizes were also limited, with 
larger groups might have made group differences more significant. Finally, levels of 
pyridoxamine in the blood should be measured to determine that levels of circulating 
pyridoxamine were increased.  
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Conclusion 
The aim of this research was to determine the mechanism by which 
pyridoxamine preserves endothelial function with age and prevents arterial stiffening. 
Pyridoxamine appears to attenuate arterial stiffening and thereby limit increases in 
PWV, however, it did not affect the formation of AGEs. Expression of antioxidant 
enzymes appeared to increase, however, proinflammatory cytokines and enzymes also 
increased, suggesting pyridoxamine’s role in oxidative stress may be multifactorial. 
Further studies are needed to identify the mechanism by which pyridoxamine prevents 
age-related arterial stiffening and preserves the vasodilatory response. 
Future Directions 
As previous studies have found correlations between arterial stiffness and 
dementia, future studies should examine cognitive function during and post-treatment 
with pyridoxamine in old animals. It is possible pyridoxamine prevents formation of 
AGEs in cerebral arteries or even brain tissue which we were unable to assess in this 
study. Thus, future studies should examine these tissues to determine whether or not 
AGEs are affected. This will provide insight into the interplay between arterial 
stiffening and cognitive decline and help elucidate the relationship between large artery 
stiffness, cerebral artery function, and cognitive function.  
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